Drug intelligence / Profile preview

ECMT-100

Development stage: Unknown
Lead developer: ECM Therapeutics
Administration: Intralesional, Topical

Overview

ECMT-100 is a biologic-derived hydrogel medical device developed by ECM Therapeutics for tissue regeneration and wound management. Composed of a naturally occurring scaffold of proteins and molecules derived from complete extracellular matrix (ECM), the product is processed into a flowable hydrogel form. It was developed based on technology from Dr. Stephen F. Badylak's lab at the University of Pittsburgh. ECMT-100 received FDA Investigational Device Exemption (IDE) approval in May 2025 for the treatment of anorectal fistulas and a variant, ECMT-100 WMD, received 510(k) clearance in June 2026 for general wound management. The product functions by promoting tissue regeneration and healing through the modulation of the extracellular matrix microenvironment.

Other names: extracellular matrix hydrogel

Beyond the preview

Go deeper on ECMT-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECMT-100.

Explore the full profile